PDF(Pubmed)
Abstract：
UNASSIGNED: This study aims to examine the potential effectiveness of intravenous neridronate (IVNer) on axial involvement in patients with spondyloarthritis (SpA) refractory to non-steroidal anti-inflammatory drugs (NSAIDs) but not eligible for biological disease-modifying antirheumatic drugs (bDMARDs).
UNASSIGNED: Patients with active SpA (BASDAI score ≥ 4) and active sacroiliitis (SI) on MRI (according to ASAS MRI definition), who were NSAID-insufficient responder/intolerant but not eligible for bDMARDs, were retrospectively recruited in a tertiary rheumatology centre between September 2015 and December 2021. IVNer (100 mg) was administered to the patients on days 1, 4, 7, and 10. Responses were evaluated 60 days after the last infusion as the median changes from the baseline of BASDAI and Visual Analogue Scale (VAS) pain and there are improvements on MRI signs.
UNASSIGNED: A total of 38 patients (26 axial SpA, 3 enteropathic arthritis, and 9 axial psoriatic arthritis) were included [66% women, mean age ± SD: 38.0 ± 14.1 years, mean disease duration: 30.5 ± 49.5 months (range 1.0-298), 47% HLAB27+]. The reason for bDMARD ineligibility was concurrent solid tumors (n = 6) or hematological (n = 1) malignancy, comorbidities (n = 11), or patient preference (n = 20). Both median BASDAI [5.83 (4.2-8.33) versus 3.66 (1.1-6.85), p < 0.001] and VAS pain [7 (5.75-8.0) versus 3 (1.0-7.0), p < 0.0001] significantly decreased after IVNer. Of 28 available MRI at follow-up, we observed a complete (36%) or partial (39%) resolution of sacroiliitis or a persistent activity (25%).
UNASSIGNED: IVNer was effective in improving axial involvement in patients with SpA refractory to NSAIDs but not eligible for bDMARDs. IVNer can be considered as a potential alternative therapeutic option in selected settings.
UNASSIGNED: Patients with active SpA (BASDAI score ≥ 4) and active sacroiliitis (SI) on MRI (according to ASAS MRI definition), who were NSAID-insufficient responder/intolerant but not eligible for bDMARDs, were retrospectively recruited in a tertiary rheumatology centre between September 2015 and December 2021. IVNer (100 mg) was administered to the patients on days 1, 4, 7, and 10. Responses were evaluated 60 days after the last infusion as the median changes from the baseline of BASDAI and Visual Analogue Scale (VAS) pain and there are improvements on MRI signs.
UNASSIGNED: A total of 38 patients (26 axial SpA, 3 enteropathic arthritis, and 9 axial psoriatic arthritis) were included [66% women, mean age ± SD: 38.0 ± 14.1 years, mean disease duration: 30.5 ± 49.5 months (range 1.0-298), 47% HLAB27+]. The reason for bDMARD ineligibility was concurrent solid tumors (n = 6) or hematological (n = 1) malignancy, comorbidities (n = 11), or patient preference (n = 20). Both median BASDAI [5.83 (4.2-8.33) versus 3.66 (1.1-6.85), p < 0.001] and VAS pain [7 (5.75-8.0) versus 3 (1.0-7.0), p < 0.0001] significantly decreased after IVNer. Of 28 available MRI at follow-up, we observed a complete (36%) or partial (39%) resolution of sacroiliitis or a persistent activity (25%).
UNASSIGNED: IVNer was effective in improving axial involvement in patients with SpA refractory to NSAIDs but not eligible for bDMARDs. IVNer can be considered as a potential alternative therapeutic option in selected settings.
摘要：
■本研究旨在研究静脉注射奈立膦酸钠（IVNer）对非甾体类抗炎药（NSAIDs）难治性脊柱关节炎（SpA）患者的轴向受累的潜在有效性，但不符合生物疾病缓解抗风湿药（bDMARDs）的条件。
■在MRI上患有活动性SpA（BASDAI评分≥4）和活动性骶髂关节炎（SI）的患者（根据ASASMRI定义），NSAID应答不足/不耐受但不符合bDMARDs的条件，我们于2015年9月至2021年12月期间在三级风湿病中心进行了回顾性招募.在第1、4、7和10天向患者施用IVNer(100mg)。在最后一次输注后60天评估反应,作为从BASDAI和视觉模拟评分(VAS)疼痛的基线的中值变化,并且在MRI征象上有改善。
■共38例患者（26例轴向SpA，3肠病性关节炎，和9个轴性银屑病关节炎)被包括在内[66%的女性，平均年龄±SD：38.0±14.1岁，平均病程：30.5±49.5个月（范围1.0-298），47%HLAB27+]。bDMARD不合格的原因是并发实体瘤（n=6）或血液学（n=1）恶性肿瘤，合并症（n=11），或患者偏好(n=20)。两者的中位数BASDAI[5.83（4.2-8.33）和3.66（1.1-6.85），p<0.001]和VAS疼痛[7（5.75-8.0）对3（1.0-7.0），p<0.0001]在IVNer后显著降低。在随访的28个可用MRI中，我们观察到骶髂关节炎完全(36%)或部分(39%)消退或持续活动(25%).
■IVNer可有效改善NSAIDs难治性SpA但不符合bDMARDs治疗条件的患者的轴向受累。IVNer可以被认为是选定环境中的潜在替代治疗选择。
■在MRI上患有活动性SpA（BASDAI评分≥4）和活动性骶髂关节炎（SI）的患者（根据ASASMRI定义），NSAID应答不足/不耐受但不符合bDMARDs的条件，我们于2015年9月至2021年12月期间在三级风湿病中心进行了回顾性招募.在第1、4、7和10天向患者施用IVNer(100mg)。在最后一次输注后60天评估反应,作为从BASDAI和视觉模拟评分(VAS)疼痛的基线的中值变化,并且在MRI征象上有改善。
■共38例患者（26例轴向SpA，3肠病性关节炎，和9个轴性银屑病关节炎)被包括在内[66%的女性，平均年龄±SD：38.0±14.1岁，平均病程：30.5±49.5个月（范围1.0-298），47%HLAB27+]。bDMARD不合格的原因是并发实体瘤（n=6）或血液学（n=1）恶性肿瘤，合并症（n=11），或患者偏好(n=20)。两者的中位数BASDAI[5.83（4.2-8.33）和3.66（1.1-6.85），p<0.001]和VAS疼痛[7（5.75-8.0）对3（1.0-7.0），p<0.0001]在IVNer后显著降低。在随访的28个可用MRI中，我们观察到骶髂关节炎完全(36%)或部分(39%)消退或持续活动(25%).
■IVNer可有效改善NSAIDs难治性SpA但不符合bDMARDs治疗条件的患者的轴向受累。IVNer可以被认为是选定环境中的潜在替代治疗选择。
